This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.
That wraps up our initial coverage of VRTX’s Q2 results. Thank you for stopping by!
Vertex Pharmaceuticals delivered a strong Q2, with revenue rising 12% year over year to $3.33 billion, GAAP net income reaching $1.1 billion, and non-GAAP net income hitting $1.2 billion.
Its cystic fibrosis franchise remained the foundation of the business, supported by strong ALYFTREK adoption, but the bigger story was the accelerating contribution from Vertex’s newer products.
CASGEVY revenue surged 151% year over year and 78% sequentially to $76 million, while JOURNAVX generated $50 million, more than quadrupling from a year earlier and climbing 71% from Q1. Vertex now expects the two products to contribute more than $500 million in combined 2026 revenue.
Management raised its full-year revenue guidance from $12.95-$13.1 billion to a new range of $13.1-$13.2 billion, while leaving its expense outlook unchanged.
That forecast excludes the pending roughly $10 billion acquisition of Crinetics Pharmaceuticals, which is expected to close in Q3 and would establish rare endocrine diseases as another major growth pillar.
Vertex also holds $13.6 billion in cash and marketable securities and faces a November 30 PDUFA decision for povetacicept in IgA nephropathy.
The quarter strengthens the diversification thesis:
Vertex Pharmaceuticals (NASDAQ:VRTX) just reported earnings, with shares initially up 1% following the report.
Key Numbers:
Quick Read:
Vertex delivered a 3.4% revenue beat, with sales climbing 12% year over year.
Adjusted EPS narrowly missed expectations by $0.02, but the strong top-line result appears to be driving the initially positive reaction.
Keep an eye on the stock into the 4:30 PM ET Q2 earnings call.
Beyond the headline numbers, the market is watching whether Vertex Pharmaceuticals (NASDAQ:VRTX) tightens or lifts its $12.95B to $13.10B FY2026 revenue range. CEO Reshma Kewalramani’s playbook has been conservative: reiterate early, narrow upward later.
A bullish scenario: Raising the top end above $13.10B, lifting the non-CF target above $500M, and pulling forward povetacicept’s launch timeline.
A bearish read: Narrowing to the low end, holding non-CF flat, or flagging heavier opex from the nephrology build.
Investors also want color on JOURNAVX prescription momentum, CASGEVY infusion cadence, and the 19.5% to 20.5% tax rate.
Historic recap: In Q3 of 2025, shares fell 10% on a beat because guidance disappointed. Tonight, forward guidance will drive the stock’s reaction just as much as the quarter’s results themselves.
Vertex Pharmaceuticals (NASDAQ:VRTX) hosts its Q2 call at 4:30 PM ET, with shares at $471.78 and put/call skewed defensively at 1.28.
This live blog is being updated by Thomas Richmond, a 24/7 Wall St. contributor. You’ll get expert analysis of Vertex Pharmaceuticals’ earnings.
Simply stay on this page, and new updates will appear below automatically. We expect VRTX to release earnings shortly after 4:00 p.m. ET.
Vertex Pharmaceuticals enters tonight’s earnings report with investors focused on the company’s emerging growth engines.
The regulatory progress for povetacicept and the broader nephrology franchise will carry significant narrative weight, while JOURNAVX and CASGEVY must again contribute meaningful growth to validate Vertex’s diversification strategy.
The first number to check will be whether management reaffirms its full-year revenue guidance of $12.95-$13.10 billion. Vertex’s 28-times trailing earnings multiple and $557.12 consensus analyst price target assume the company can successfully layer nephrology, pain, and cell therapy revenue onto its mature cystic fibrosis franchise.
A reaffirmed outlook with visible non-CF traction would support that thesis, while a guidance cut or softer JOURNAVX results could revive concerns about the pace of diversification.
Live coverage has ended. The full story is below.
Vertex Pharmaceuticals (NASDAQ:VRTX | VRTX Price Prediction) reports Q2 2026 results tonight at around 4:05 PM ET, with the call scheduled for 4:30 PM ET. The report lands as investors weigh a busy M&A stretch against slower revenue momentum in the core cystic fibrosis franchise.
Q1 2026 set an uneven tone. Vertex delivered EPS of $4.47 versus $4.31 consensus but revenue of $2.9869B missed by 0.36%, even as operating income jumped 80.62% YoY. CEO Reshma Kewalramani highlighted that “CASGEVY and JOURNAVX delivered more than 25% of our growth this quarter.”
Today, shares trade at about $473.52, up 5.24% YTD but down 4.2% over the past month. The $10 billion Crinetics acquisition and the $28 million upfront AbCellera T-cell engager deal reshaped the pipeline narrative in the final week before this earnings report.
| Metric | Q2 2026 Est. | YoY Change | FY 2026 Est. |
|---|---|---|---|
| Revenue | ~$3.19B | +7.6% | $12.95B-$13.10B |
| EPS (Non-GAAP) | $4.30 | -4.9% | n/a |
The $4.30 EPS consensus sits below the $4.52 in EPS Vertex reported in Q2 2025, signaling that analysts have baked in elevated opex from the JOURNAVX launch and the nephrology build. Revenue expectations of roughly 7.6% YoY growth reflect a step down from FY2025’s 8.9% pace.
Tonight, I’ll be watching povetacicept commentary first. The rolling BLA for IgA nephropathy is complete, and management is using a Priority Review Voucher for a six-month expedited review. Timing color on the FDA decision moves the nephrology franchise story.
JOURNAVX prescription cadence is another area for key focus. Vertex disclosed more than 1 million prescriptions filled since the March 2025 launch, with Medicare Part D coverage adding roughly 10 million lives effective May 1. The Q2 number sets the baseline for the $500M+ non-CF revenue target.
I’ll also track CASGEVY infusion volumes, ALYFTREK ex-US uptake following new reimbursement in Scotland, Spain, Sweden, Switzerland, New Zealand, Israel, and Finland. Insider activity has skewed toward selling across 16 recent transactions, a contrarian datapoint against an analyst base with 27 buy versus 2 sell ratings.
| Quarter | EPS Surprise | Day-Of Move | 1-Week Move | 30-Day Move |
|---|---|---|---|---|
| Q1 2026 | +3.81% | -1.28% | +5.64% | +5.3% |
| Q4 2025 | -2.33% | +5.69% | -2.13% | -8.11% |
| Q3 2025 | +4.87% | -1.02% | +1.79% | +8.02% |
| Q2 2025 | +6.33% | -20.6% | +3.41% | +5.64% |
On average, shares moved roughly +0.94% one week after earnings across the past five quarters.
Contact [email protected] for any questions or corrections.
Thomas Richmond is a financial writer and content strategist with 5+ years of experience covering stocks and financial markets. He has published over 500 articles focused on individual stock analysis, helping investors better understand business fundamentals, stock valuations, and long-term opportunities.
Thomas previously served as a Content Lead at TIKR, a stock research platform, where he helped scale the company’s blog to hundreds of articles per month and contributed to a weekly newsletter reaching more than 100,000 investors.
Outside of work, Thomas enjoys weight lifting and soccer.
Vertex Pharmaceuticals (NASDAQ:VRTX | VRTX Price Prediction) screens as a long-duration compounder because it sits on a global monopoly in cystic fibrosis therapies that generates substantial free cash, while Wall Street prices it closer…
Buy-and-hold investing is a time-tested strategy that rewards patience and discipline. By owning high-quality stocks for at least three to five years, preferably a decade or more, investors can harness the power of compounding…
Crinetics Pharmaceuticals (NASDAQ:CRNX | CRNX Price Prediction) shares have climbed 99% just this week, from $42.03 at Monday’s close, to $83.54 earlier today. The simple reason: Vertex Pharmaceuticals (NASDAQ:VRTX) agreed to acquire it. Vertex’s…
On CNBC’s Mad Dash segment on Monday, July 6, 2026, Jim Cramer made one of his most bullish biotech calls in years, arguing that the sector could be entering a new wave of mergers…
Companies announce stock splits all the time, and so far this year a number of high profile companies have divvied up their shares into smaller slices. Walmart (NYSE:WMT | WMT Price Prediction) split its…
The death crosses flashing on both Hershey (NYSE: HSY | HSY Price Prediction) and Vertex Pharmaceuticals (NASDAQ: VRTX) are a bearish technical signal that Wall Street is openly ignoring. Analyst consensus on both stocks…
CNBC’s Jim Cramer pushed viewers away from the usual semiconductor and hyperscaler chatter. Instead, he highlighted a group he says has quietly become the market’s leader. “There is a move in biotech that we…
Your challenge as an investor is to look for the bigger story. When it comes to a biotech company like Vertex that means looking at the pipeline.
Sometimes after a stock has a good run, the analysts on Wall Street start to get a little gun-shy, especially if they made a good call on the stock and it went up smartly.
